European Cardiology Review · 2 authors, 1 centre
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This review summarizes the discovery and clinical translation of PCSK9 inhibition, highlighting that monoclonal antibodies (evolocumab, alirocumab) reduce LDL-C by ~60% and cardiovascular events, while siRNA therapy (inclisiran) lowers LDL-C by ~50% with twice-yearly dosing. Emerging oral, gene-editing, and vaccine strategies promise to expand access and reduce costs, further revolutionizing lipid management.
**Background** The discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) in 2003 revolutionized understanding of cholesterol homeostasis. Gain-of-function mutations in PCSK9 cause autosomal dominant hypercholesterolemia with elevated LDL cholesterol (LDL-C), while loss-of-function (LOF) mutations result in lifelong low LDL-C and dramatic cardiovascular protection. In the Dallas Heart Study, nonsense mutations (Y142X, C679X) reduced LDL-C by 40%; in ARIC, these mutations occurred in 2.6% of black participants (28% LDL-C reduction) and R46L in 3.2% of white participants (15% reduction), corresponding to hazard ratios for cardiovascular disease of 0.11 (95% CI 0.02–0.81) and 0.50 (95% CI 0.32–0.79), respectively. PCSK9 normally binds to the LDL receptor (LDLR) on hepatocytes, preventing its recycling and reducing LDL clearance. Inhibiting PCSK9 increases LDLR density, enhancing LDL-C clearance.
**Methods** This is a narrative review summarizing the development, clinical trials, and emerging therapies targeting PCSK9. Key trials discussed include FOURIER (27,564 participants with ASCVD, evolocumab vs placebo, median 2.2 years), ODYSSEY OUTCOMES (18,924 participants with recent acute coronary syndrome, alirocumab vs placebo, median 2.8 years), and the ORION program (Phase III pooled analysis of 3,660 participants, inclisiran vs placebo, 540 days). Emerging therapies include oral MK-0616 (Phase IIb), oral ASO AZD0780 (Phase I), CRISPR base editor VERVE-101 (Phase Ib), and vaccines AT04A (Phase I) and VXX-401 (preclinical).
**Key Results** - Monoclonal antibodies: Evolocumab reduced LDL-C by ~60% and cardiovascular events (9.8% vs 11.3% in FOURIER). In FOURIER-OLE (average 7.1 years), evolocumab sustained 15% lower risk of major adverse cardiovascular events (HR 0.85; 95% CI 0.75–0.96). Alirocumab reduced recurrent events (9.5% vs 11.1% in ODYSSEY OUTCOMES); those with baseline LDL-C ≥100 mg/dl had greatest benefit (HR 0.78; 95% CI 0.69–0.89). Both also lower lipoprotein(a) by ~25–27%. - siRNA (inclisiran): In pooled Phase III data, placebo-corrected LDL-C reduction was 50.7% (95% CI 48.4–52.9). Exploratory cardiovascular endpoint showed benefit (OR 0.74; 95% CI 0.58–0.94). In ORION-3, mean LDL-C reduction over 4 years was 44.2% (95% CI 41.4–47.1). - Oral MK-0616: Phase I data showed LDL-C reduction of 65% after 14 days. - CRISPR (VERVE-101): In non-human primates, a single dose reduced PCSK9 by 83% and LDL-C by 69% at 476 days, with no germline editing. - Vaccine (AT04A): Phase I showed 7.2% LDL-C reduction overall; those with highest antibody titers had ~40% reduction.
**Clinical Implications** PCSK9 inhibitors are approved as adjuncts to maximally tolerated statin therapy for ASCVD, primary hypercholesterolemia, or mixed dyslipidemia. The 2019 ESC/EAS guidelines recommend them when LDL-C goals are not met. Long-term safety data (FOURIER-OLE) show no cognitive impairment or other adverse effects from very low LDL-C. Cost remains a barrier (~$6,000/year), but emerging oral and gene-editing therapies may improve access. Ongoing trials (VESALIUS-CV, ORION-4, VICTORION-2 PREVENT) will further define cardiovascular benefits in broader populations.